Company news

Avacta Group PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Presentations of pre|CISION® Platform Candidates

March 17, 2026

Phase 1 study opening for AVA6103

March 16, 2026

PreCISION payload delivery advantage over ADC

February 24, 2026

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

February 24, 2026

Avacta to Participate in Conference March 2026

February 18, 2026

Appointment of CSO

February 9, 2026

Avacta appoints Francis Wilson as Chief Scientific Officer

February 9, 2026

Faridoxorubicin Program Clinical Updates

February 3, 2026

Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program

February 3, 2026

Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)

January 21, 2026

FDA Clearance of IND Application for AVA6103

January 21, 2026

Year-end trading update

January 20, 2026

Avacta Announces Year-end Trading Update

January 20, 2026

Appointment of Nominated Adviser & TVR

January 20, 2026

Avacta reports new AVA6103 pharmacology data

December 18, 2025

Faridoxorubicin Phase 1b SGC data

December 17, 2025

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

December 17, 2025

Preliminary Data in Faridoxorubicin Phase 1b Trial

December 8, 2025

Completion of Placing and TVR

November 3, 2025

Block Listing Six Monthly Return

October 27, 2025

Avacta presents preclinical data at AACR-NCI-EORTC

October 27, 2025

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

October 25, 2025

Notice of Investor Presentation

October 23, 2025

Equity fundraise of £16 million

October 20, 2025

Avacta Presents Phase 1a Data for Faridoxorubicin

October 20, 2025

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress

October 19, 2025

Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium

October 13, 2025

Avacta to present data at EORTC-NCI-AACR

October 13, 2025

Interim Half Year Results 2025

September 30, 2025

Notice of Interim Results

September 15, 2025

Shortlisted for AIM Awards Technology of the Year

September 9, 2025

Avacta completes sale of Coris Bioconcept

September 1, 2025

Amendments to Convertible Bond + equity fundraise

August 29, 2025

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress

July 30, 2025

Avacta to Present at ESMO Congress

July 30, 2025

Agreement to Sell Coris Bioconcept SRL

July 28, 2025

Payment of Convertible Bond Installment

July 21, 2025

Equity fundraise of £3.25 million

July 17, 2025

Result of AGM

July 2, 2025

Q2 2025 Business Update

July 2, 2025

Management Team Appointments

July 1, 2025

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

July 1, 2025

Appointment of Zeus Capital as Joint Broker

June 30, 2025

New Response in Phase 1b Trial

June 19, 2025

Posting of Annual Report and Revised Notice of AGM

June 9, 2025

Preliminary Full Year 2024 Results

June 6, 2025

Avacta Change in Prelim Date Part 2

June 4, 2025

Board appointments

May 28, 2025

Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors

May 28, 2025

Update on timing of preliminary results

May 27, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.